Why IMU is a multi multi bagger, page-21876

What he means is that when you write: "whilst many critics may see Her Vaxx as a fail, it definitely is not"

But then write: "The difficulty is in marrying it with a Big Pharma pipeline in combination with their existing suite of products .... Therefore reaching a sound commercial outcome has proven difficult for Imugene"

You're missing the elephant in the room. Which is after 10 years and tens of millions spent, failing to achieve a commercial outcome for HER-Vaxx is "definitely a fail".

I'd add that failing to admit it and failing to keep shareholders informed compounds the scientific fail with a bit of management-can't-be-trusted fail.